pirfenidone has been researched along with cyclosporine in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Arai, Y; Isogane, N; Ito, K; Ogawa, C; Otomo, M; Sano, Y; Sekiya, T; Suzuki, N; To, Y | 1 |
| Andoh, TF; Bennett, WM; Shihab, FS; Yi, H | 2 |
| Dosanjh, A; Ikonen, T; Morris, RE; Wan, B | 1 |
| Latham, CW; Margolin, SB; Visner, GA; Zander, DS; Zhou, H | 1 |
| Dosanjh, A | 1 |
| Fratianni, C; Gonzales, M; Khardori, R; Mamillapali, C | 1 |
| Wang, L; Zhang, FC; Zhang, X | 1 |
| Asano, K; Enokida, K; Hattori, S; Hayama, N; Hirabayashi, K; Horio, Y; Ito, Y; Miyaoka, M; Niimi, K; Oguma, T; Ohshinden, K; Takahashi, F; Takahashi, G; Takahashi, M; Takiguchi, H; Takihara, T; Tanaka, J | 1 |
| Chen, Y; Deng, L; Hu, X; Zhang, Y; Zhou, J | 1 |
2 review(s) available for pirfenidone and cyclosporine
| Article | Year |
|---|---|
Immunotherapy in miscellaneous medical disorders Graves ophthalmopathy, asthma, and regional painful syndrome.
Topics: Allergens; Anti-Asthmatic Agents; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antioxidants; Asthma; Azathioprine; Benzamides; Complex Regional Pain Syndromes; Cyclosporine; Decompression, Surgical; Etanercept; Glucocorticoids; Graves Ophthalmopathy; Humans; Imatinib Mesylate; Immunoglobulin G; Immunoglobulins, Intravenous; Immunosuppressive Agents; Immunotherapy; Octreotide; Omalizumab; Orbit; Piperazines; Pyridones; Pyrimidines; Radiotherapy Dosage; Receptors, Tumor Necrosis Factor; Risk Factors; Rituximab; Selenium | 2012 |
Therapeutic advances for primary biliary cholangitis: the old and the new.
Topics: Abatacept; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cyclosporine; Enzyme Inhibitors; Fibric Acids; Glucocorticoids; Humans; Immunosuppressive Agents; Indoles; Liver Cirrhosis, Biliary; Mesenchymal Stem Cell Transplantation; Methotrexate; Mycophenolic Acid; Pyridones; Rituximab; Tacrolimus; Ursodeoxycholic Acid; Ustekinumab | 2016 |
10 other study(ies) available for pirfenidone and cyclosporine
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
[Successful treatment of steroid-resistant bronchiolitis obliterans-organizing pneumonia with orally administered cyclosporin and pirfenidone].
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Cryptogenic Organizing Pneumonia; Cyclosporine; Drug Therapy, Combination; Humans; Male; Methylprednisolone; Pyridones; Treatment Outcome | 2000 |
Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biglycan; Calcinosis; Creatinine; Cyclosporine; Extracellular Matrix Proteins; Humans; Immunohistochemistry; Immunosuppressive Agents; Kidney; Kidney Diseases; Kidney Tubules; Male; Proteoglycans; Pyridones; Rats; Rats, Sprague-Dawley; RNA, Messenger; Transcription, Genetic; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2002 |
Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclosporine; Cytokines; Cytotoxicity Tests, Immunologic; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Graft Rejection; Immunosuppressive Agents; Pyridones; Rats; Rats, Inbred Lew; Staining and Labeling; Trachea | 2002 |
Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity.
Topics: Animals; Apoptosis; bcl-X Protein; Caspase 3; Caspases; Cyclosporine; Fas Ligand Protein; Gene Expression Regulation; Genes, p53; In Situ Nick-End Labeling; Kidney; Male; Membrane Glycoproteins; Proto-Oncogene Proteins c-bcl-2; Pyridones; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2005 |
Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cyclosporine; Disease Models, Animal; Female; Graft Rejection; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyridones; Sirolimus; Trachea; Transforming Growth Factor beta | 2005 |
Pirfenidone and chronic progressive obliterative airway disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bronchiolitis Obliterans; Cyclosporine; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Immunosuppressive Agents; Mice; Proteins; Pyridones; Rats | 2006 |
Regression of Lung Squamous Cell Carcinoma after the Withdrawal of Cyclosporin A Combined with Pirfenidone Treatment in a Patient with Idiopathic Pulmonary Fibrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; Cyclosporine; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Neoplasms; Male; Pyridones; Treatment Outcome | 2021 |
Case Report: Successful Treatment of Refractory Interstitial Lung Disease With Cyclosporine A and Pirfenidone in a Child With SLE.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child, Preschool; Cyclosporine; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Lupus Erythematosus, Systemic; Male; Pyridones | 2021 |